Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Henry Ji
|
| gptkbp:collaboratedWith |
gptkb:Celularity
Mabpharm SmartPharm Therapeutics |
| gptkbp:developedBy |
Abivertinib
COVI-GUARD COVI-STIX Darvasertib Resiniferatoxin SP-102 (SEMDEXA) ZTlido |
| gptkbp:filedForBankruptcy |
2023
|
| gptkbp:focusesOn |
infectious diseases
oncology pain management immunotherapy antibody-drug conjugates COVID-19 therapeutics |
| gptkbp:foundedIn |
1989
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sorrento Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:subsidiary |
Scilex Holding Company
|
| gptkbp:tradedOn |
SRNE
|
| gptkbp:website |
https://www.sorrentotherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:PT-1880
gptkb:WuXi_Biologics |
| gptkbp:bfsLayer |
7
|